GLMD Stock Catalyst: Galmed Pharmaceuticals to Acquire Colospan, Targeting $6 Billion GI Market

Jun 8, 2026 · 5:13pm ET

The acquisition aims to create a GI-focused platform.

Max move

+73.5%

High of day $0.85

Sparker timei

5:13pm ET

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Galmed Pharmaceuticals announced Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market.

The announcement cited $6 Billion.

Galmed Pharmaceuticals Ltd. has a free float of 5,413,835 shares and 6,581,390 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GLMD sparks.

Catch the next GLMD-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.